Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Mismatch-repair deficient (MSI-high) colorectal cancer, drawn from the whole corpus: 23 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
A third of metastatic patients progress early on immunotherapy and the resistance mechanisms are only partly understood.
Nothing recorded yet.
Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Whether surgery can be omitted after complete response in colon, as in rectal, cancer is untested.
WRN helicase inhibitors, a synthetic-lethal approach, are in early trials.
Lynch carriers still get cancers between colonoscopies; a preventive vaccine is in randomised testing.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 15 changes by month →When this page itself was last checked or edited.
Primary endpoint (sustained cCR at 12 months) met; rates pending congress presentation.
With nivolumab first-line MSI-H/dMMR colorectal cancer (CheckMate 8HW)
3-year DFS 86.
A milestone in how this cancer is treated.
First-line PFS 54.